Ikena Oncology (IKNA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IKNA Ikena Oncology

Watchlist

1.680
-0.020-1.18%

Trading Dec 4 14:08 ET

81.07MMarket Cap-1365P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Ikena Oncology(IKNA.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsNov 11 06:33 ET · Ratings
Buy Rating for Ikena Oncology Driven by Promising IK-595 Developments
TipRanksNov 11 06:27 ET · Ratings
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 Loss per Share (Vs US$0.40 Loss in 3Q 2023)
Yahoo FinanceNov 9 09:47 ET
Ikena Oncology Reports Strategic Realignment and Financial Performance
TipRanksNov 8 01:00 ET
Ikena Oncology GAAP EPS of -$0.21 Beats by $0.06
Seeking AlphaNov 7 11:21 ET
Ikena Oncology 3Q Loss $10.2M >IKNA
Dow JonesNov 7 08:33 ET

Comments

Trytosaveabit

May 28 18:58

$Ikena Oncology (IKNA.US)$ I did say 2 weeks ago that data was coming! And they were looking for a possible partner!

Jaguar8

May 28 15:18

NEWS

$Ikena Oncology (IKNA.US)$
Ikena Oncology Announces Strategic Update
Ikena Oncology announced they are discontinuing the development of IK-930, their TEAD1-selective Hippo pathway inhibitor. The company will continue the clinical development of IK-595, a MEK-RAF molecular glue showing promising PK and PD data in RAS and RAF mutant cancers. Ikena ended Q1 with $157.3 million in cash and is projecting $110-$120 million by year-end 2024. The company is exploring strategic options, including part...

Trytosaveabit

Mar 12 17:51

Just a hint! Maybe keep a eye on closely?

$Ikena Oncology (IKNA.US)$ They are looking for a licensing partner for one or more of their drugs in pipeline! Also expecting some data release in Q2!